Nuance Investments LLC Boosts Stake in Kenvue Inc. $KVUE

Nuance Investments LLC lifted its stake in Kenvue Inc. (NYSE:KVUE) by 294.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,813,985 shares of the company’s stock after purchasing an additional 2,100,583 shares during the period. Kenvue accounts for approximately 5.3% of Nuance Investments LLC’s holdings, making the stock its 7th largest holding. Nuance Investments LLC owned about 0.15% of Kenvue worth $48,541,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new position in Kenvue during the fourth quarter worth about $26,000. Physician Wealth Advisors Inc. lifted its holdings in Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after acquiring an additional 618 shares in the last quarter. Cornerstone Planning Group LLC lifted its holdings in Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after acquiring an additional 1,361 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in Kenvue by 82.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after acquiring an additional 1,027 shares in the last quarter. Finally, Leonteq Securities AG bought a new position in Kenvue during the fourth quarter worth about $45,000. 97.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on KVUE. Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 29th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Canaccord Genuity Group lifted their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Barclays reduced their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 14th. Finally, Zacks Research upgraded Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $19.33.

Kenvue Price Performance

NYSE:KVUE opened at $17.72 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. The stock’s 50-day simple moving average is $17.37 and its 200 day simple moving average is $17.48. The company has a market cap of $34.01 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.28 and a beta of 0.54. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.Kenvue’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 earnings per share. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. Kenvue’s payout ratio is currently 97.65%.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.